Clinical Trials Management Services LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$81,647	21
2024	Research	$47,111	2
2023	Research	$17,700	1

Breakdown

Who paid Research payments · program years 2023–2025

Moderna TX, Inc. $61,134 19 payments
Amgen Inc. $53,124 3 payments
Sanofi US Services Inc. $17,700 1 payment
Eli Lilly and Company $14,500 1 payment

Studies the money was for Research payments · program years 2023–2025

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $61,134 19 payments
P2 UC $47,111 2 payments
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype $17,700 1 payment
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone Or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis $14,500 1 payment
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis $6,013 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.